Cor Vasa 2012, 54(7-8):419-423

Kombinační léčba k dosažení cílových hodnot LDL cholesterolu

Prof. MUDr. Richard Češka, CSc.
Centrum preventivní kardiologie, III. interní klinika, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice, Praha

Keywords: Apolipoprotein B; Ezetimib; LDL cholesterol; Niacin; Pryskyřice; Statiny

Published: July 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češka R. Kombinační léčba k dosažení cílových hodnot LDL cholesterolu. Cor Vasa. 2012;54(7-8):419-423.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hradec J, Bultas J, Kmínek A, et al. Jak se léčí statiny v České republice? Výsledky průzkumu STEP. Cor Vasa 2011;53:527-34. Go to original source...
    2. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomised controlled trial. JAMA 2004;291:1071-80. Go to original source... Go to PubMed...
    3. Ballantyne M, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study. Am Heart J 2005;149:464-73. Go to original source... Go to PubMed...
    4. Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94. Go to original source... Go to PubMed...
    5. Kastelein J. What future for combination therapies? Int J Clin Pract Suppl 2003;(134):45-50.
    6. Stone N. Combination therapy: its rationale and the role of ezetimibe. Eur Heart J Suppl 2002;4:J19-J22. Go to original source...
    7. SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010;160:785-94. Go to original source... Go to PubMed...
    8. Rossebo AB, Pedersen TR, Boman K, et al., for the SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56. Go to original source... Go to PubMed...
    9. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81. Go to original source...
    10. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55. Go to original source...
    11. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98. Go to original source... Go to PubMed...
    12. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes